{"funded_research":"<p>1.\u00a0 National Institute of General Medical Sciences Medical Scientist Training Program, role: <strong>Training Grant Recipient</strong>, 8/93-8/94.</p>\n\n<p>2.\u00a0 5 F30 MH10819 Predoctoral National Research Service Award, \u201cNeuropsychological Indicators of Risk for Schizophrenia,\u201d role: <strong>Principal Investigator</strong>, 9/94-5/00.</p>\n\n<p>3.\u00a0 NARSAD (Young Investigator Award), \u201cHypothalamic-Pituitary-Adrenal Function in Adults with a History of Childhood Parental Loss,\u201d role: <strong>Principal Investigator</strong>; 6/03-5/05, &#36;60,000.</p>\n\n<p>4.\u00a0 Janssen Pharmaceutica Faculty Development Award in Psychopharmacology, role: <strong>Principal Investigator</strong>, 5/18/03, &#36;25,000.</p>\n\n<p>5.\u00a0 RSGPB PBP-103382 American Cancer Society, \u201cImproving Smoking Cessation in Smokers with<br />\nDepressive Symptoms\u201d, role: <strong>Study Physician</strong>, 7/02-6/04</p>\n\n<p>6.\u00a0 Medtronic, Inc., \u201cElectrical Stimulation of the Anterior Limb of the Internal Capsule to Treat Major Depressive Disorder,\u201d role: <strong>Co-Investigator</strong>, 10/02-9/04, &#36;315,000.</p>\n\n<p>7.\u00a0 K23MH067947 Mentored Patient-Oriented Research Career Development Award, \u201cRisk for Depression, Stress, and Neuroendocrine Function,\u201d role: <strong>Principal Investigator</strong>; 12/03-11/08,\u00a0 &#36;905,000.</p>\n\n<p>8.\u00a0 Pfizer, Inc. \u201cSertraline Treatment and Cortisol Response to the DEX/CRH Test\u201d, Investigator-Initiated, role: <strong>Co-Investigator</strong>, 1/04-11/06, &#36;300,684.</p>\n\n<p>9.\u00a0 United States Department of the Interior, \u201cPerceived Early Life Stress and DEX/CRH Test Response as Predictors of Psychological Sequelae following Exposure of Healthy Adults to War Stress,\u201d role: <strong>Co-Investigator</strong>, 7/04-6/05, &#36;40,000</p>\n\n<p>10. UCB Pharma, Inc. \u201cKeppra Treatment and Cortisol Response to the DEX/CRH Test in Healthy Subjects,\u201d Investigator-Initiated, role: <strong>Co-Investigator</strong>, 6/04-5/07, &#36;111,624.</p>\n\n<p>11. NCCAM/NIMH AT001742, \"Double-blind, placebo-controlled study of SAMe vs. escitalopram in MDD,\" role: <strong>Study Physician</strong>, 4/04 - 3/09,\u00a0 &#36;1,087,938.</p>\n\n<p>12. United States Department of Defense, \u201cBiomarkers of risk for post-traumatic stress disorder (PTSD),\u201d role: <strong>Principal Investigator</strong>, 4/01/07-4/01/10, &#36;409,390.</p>\n\n<p>13. Cyberonics, Inc. \u201cRandomized Comparison of Outcomes in Patients with Treatment-Resistant Depression Who Receive VNS Therapy Administered at Different Amounts of Electrical Charge\u201d \u00a0role: <strong>Co-Investigator</strong>; 11/1/07-12/1/10; &#36;230,000.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0</p>\n\n<p>14. Medtronic, Inc. \u00a0\u201cRECLAIM Deep Brain Stimulation (DBS) Clinical Study for Treatment- Resistant Depression.\u201d Multi-Site;\u00a0 role: <strong>Sub-Investigator</strong> 4/16/2009-5/1/2012, &#36;329,280.</p>\n\n<p>15. R01 MH0687670 \u201cDEX/CRH Response: Mood/Anxiety Disorder Endophenotype? Phase 2.\u201d role: <strong>Co-Investigator</strong>, 12/08-11/13, &#36;3,514,780.</p>\n\n<p>16. R01 MH083704 \u201cChildhood Maltreatment: Biomarkers of Risk and Resilience,\u201d role: <strong>Principal Investigator</strong>, 12/09-11/14, &#36;2,863,342.</p>\n\n<p>17. R01 NR012005 \u201cRCT of Hatha Yoga for Persistent Depression,\u201d role: <strong>Co-Investigator</strong>, 2/11 - 01/15, &#36;1,718,041.</p>\n\n<p>18. R21 MH091508 \u201cChildhood Maltreatment: Epigenetic Modulation of the Glucocorticoid Receptor,\u201d role: <strong>Principal Investigator</strong>, 4/08/11-3/31/13,\u00a0 \u00a0 &#36;393,156.</p>\n\n<p>19. R01MH068767 - 08W1 Supplement to \u201cDEX/CRH Response: Mood/Anxiety Disorder Endophenotype? Phase 2.\u201d Telomere Shortening in Relation to Early-Life Stress, role: <strong>Co-Investigator</strong>, 5/8/12-4/30/13, &#36;60,000.</p>\n\n<p>20. R01 MH083704-Supplement to \u201cChildhood Maltreatment: Biomarkers of Risk and Resilience,\u201d role: <strong>Principal Investigator</strong>, 07/29/12-11/30/2014, &#36;185,143.</p>\n\n<p>21. R34 MH099310 \u201cTestosterone Augmentation in Women,\u201d role: <strong>Co-Investigator</strong>, 6/30/13-6/30/15, &#36;633,150.</p>\n\n<p>22. HHSN2712011000061 \u201cRapidly Acting Treatments for Treatment-Resistant Depression (RAPID),\u201d role: <strong>Co-Investigator</strong>, 4/1/14-3/31/16, &#36;341,269.</p>\n\n<p>23. Brown Institute for Brain Science / Norman Prince Neurosciences Institute New Frontiers Award \u201cDevelopmental Response to Early Stress: Neural Mechanisms of Cognitive and Behavioral Effects,\u201d role: <strong>Co Principal Investigator</strong>, 1/1/14-12/31/14, &#36;40,000.</p>\n\n<p>24. 1 R01 MH101107 \u201cEarly Life Stress: Epigenetic Regulation of Endocrine and Immune Pathways,\u201d role: <strong>Principal Investigator</strong>, 4/1/2014-3/31/2019, &#36;2,639,488.</p>\n\n<p>25. 1 R01 NR014540-01A1 \u201cRCT of a Tailored Walking Program to Reduce Stress Among Pregnant Women,\u201d role: <strong>Co-Investigator</strong>,\u00a0 9/17/14-9/16/19, 2,358,850.</p>\n\n<p>26.\u00a0 R01MH105379-01 \u201cBiomarkers, Social, and Affective Predictors of Suicidal Thoughts and Behaviors in Adolescents\u201d, role: <strong>Co-Investigator</strong>, 3/1/15-2/28/19, &#36;3,230,458.</p>\n\n<p>27.\u00a0 1R25MH101076 \u201cPromoting Research Training During Psychiatry Residency,\u201d role: <strong>Principal Investigator</strong>, 7/1/13-6/30/18, &#36;989,310.</p>\n\n<p>28.\u00a0 1R25MH101076 S1 Supplement to \u201cPromoting Research Training During Psychiatry Residency\u201d to support the National Neuroscience Curriculum Initiative. role: <strong>Principal Investigator</strong>, 7/1/13-6/30/18, &#36;989,310.</p>\n\n<p>29.\u00a0 TACO / The White Family Foundation Grant to fund purchase of a spectrophotometer, <strong>Principal Investigator,</strong> 1/1/2016, &#36;5,000.</p>\n\n<p>30.\u00a0 Brown Institute for Brain Science / Norman Prince Neurosciences Institute New Frontiers Award \u201cMolecular Mechanisms of the Impact of Early Adversity on Neuronal Development: Focus on Mitochondria,\u201d role: <strong>Co Principal Investigator</strong>, 5/1/16-4/30/17, &#36;40,000.</p>\n\n<p>31.\u00a0 1R01HD086487-01\u00a0\u00a0\u201cRisk Profiles and Mechanisms of Disease in Maltreated Children,\u201d role: <strong>Principal Investigator</strong>, 9/21/16-5/31/21, &#36;2,962,164.</p>\n\n<p>32.\u00a0 1F31HD088020-01A1 \u201cBiological Indicators of Trauma in Foster Youth: The Role of Social Support,\u201d role: <strong>Co-Mentor</strong>, 4/25/17-4/24/19, &#36;76,488.</p>\n\n<p>33.\u00a0 Roddy Holden Kinzel Foundation equipment grant \u201cChildhood Adversity and Mitochondrial Function,\u201d <strong>Principal Investigator</strong>, 12/1/17, &#36;10,000.</p>\n\n<p>34.\u00a0 Brown Institute for Brain Science / Norman Prince Neurosciences Institute New Frontiers Award \u201cMolecular Mechanisms of the Impact of Early Adversity on Neuronal Development: Focus on Mitochondria, Phase II\u201d role: <strong>Co Principal Investigator</strong>, 5/1/17-4/30/18, &#36;40,000.</p>\n\n<p>35. Ida Ballou Littlefield Foundation equipment grant \u201cEarly Life Stress and Mitochondrial Function,\u201d <strong>Principal Investigator</strong>, 1/17/18, &#36;7,500.</p>\n\n<p>36. 3R25MH101076-05S2 Supplement to \u201cPromoting Research Training During Psychiatry Residency\u201d to support a summer research fellowship in psychiatry for medical students from under-represented minority groups, role: <strong>Principal Investigator</strong>, 6/21/18-8/03/18, &#36;10,433.</p>\n"}
